Digitally enabled technologies to support treatment with weight-management medication in specialist weight-management services: early value assessment

Evidence generation

4.1 Four technologies (Liva, Oviva, Roczen and Second Nature) can be used in the NHS to address the unmet need, with appropriate safety processes in place. Further evidence will be generated while they are being used. The key outcomes prioritised by the committee for evidence generation are outlined in section 1.6. Other important outcomes include change in body mass index (BMI), programme engagement, rates and reasons for stopping the programme, health-related quality of life and psychological outcomes. Further information will be included in the evidence generation plan.

Research only recommendations

4.2 The committee concluded that there was not enough clinical-effectiveness evidence to recommend CheqUp, Gro Health W8Buddy and Wellbeing Way for use in the NHS, other than as part of a research study.

4.3 Research should include well-designed and adequately powered studies with appropriate comparators. The key outcomes prioritised by the committee are outlined in section 1.6 and further important outcomes are outlined in section 4.1. Research studies should address the evidence gaps outlined in this guidance to assess the benefit of using these technologies to support treatment with weight-management medications in adults.